Category - Developments

Developments

Aravive completes enrolment in Phase 3 ovarian cancer trial

Aravive (NASDAQ:ARAV) achieved full enrollment in a global registrational Phase 3 trial of batiraxcept plus paclitaxel for platinum-resistant ovarian cancer (PROC). The Phase 3 AXLerate-OC trial is evaluating efficacy...

January 4, 2023

Developments

Kiora completes enrollment in persistent corneal epithelial defects trial

Kiora Pharmaceuticals (NASDAQ:KPRX) completed enrollment in its clinical study evaluating KIO-201 in patients with persistent corneal epithelial defects (PCED), a rare ocular condition characterized by non-healing...

January 3, 2023

Developments

Profound Medical CEO adds to holdings, again

According to a filing with SEDI, Profound Medical (NASDAQ:PROF; TSX:PRN) chairman and CEO, Arun Menawat, acquired 13,000 shares of the company at a price of $7.81 (U.S.) each on the open market to hold 425,296 shares...

December 21, 2022

Developments

Zymeworks posts positive pivotal topline data in BTC

Zymeworks (NASDAQ ZYME) reported positive topline results from the pivotal Phase 2b HERIZON-BTC-01 open-label, single-arm clinical trial investigating zanidatamab, a HER2-targeted bispecific antibody, as monotherapy in...

December 19, 2022

Developments

Avidity posts first-ever data targeting delivery of RNA to muscle

Avidity Biosciences (NASDAQ:RNA) reported positive AOC 1001 data from the preliminary assessment of the Phase 1/2 MARINA trial, demonstrating the first-ever successful targeted delivery of RNA into muscle, a...

December 14, 2022

Developments

PharmaJet partner gets fast track for cancer vaccine

PharmaJet partner, Immunomic Therapeutics, received FDA fast track designation for a clinical study of its plasmid DNA vaccine, ITI-3000, in patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin...

December 13, 2022

Developments

MAIA Biotechnology expands Phase 2 THIO-101 trial to Europe

Regulatory authorities in three European countries, Hungary, Poland, and Bulgaria, have approved implementation of MAIA Biotechnology’s (NASDAQ:MAIA) THIO-101, the company’s Phase 2 clinical trial evaluating its lead...

December 13, 2022

Developments

Indaptus initiates Phase 1 trial of Decoy20 in advanced solid tumors

Indaptus Therapeutics (NASDAQ:INDP) initiated INDP-D101, its first-in-human, open label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound, Decoy20, in patients with...

December 13, 2022

Developments

UT Southwestern performs 100th procedure with Profound’s TULSA-PRO

UT Southwestern in Dallas, one of the nation’s premier academic medical centers, performed its 100th procedure with Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO, an innovative MRI-guided minimally invasive...

December 9, 2022

Developments

Context posts encouraging preliminary Phase 2 data in breast cancer

Context Therapeutics (NASDAQ:CNTX) reported preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s orally administered progesterone receptor (PR) antagonist, in...

December 8, 2022

Category - Developments

Aravive completes enrolment in Phase 3 ovarian cancer trial

Kiora completes enrollment in persistent corneal epithelial defects trial

Profound Medical CEO adds to holdings, again

Zymeworks posts positive pivotal topline data in BTC

Avidity posts first-ever data targeting delivery of RNA to muscle

PharmaJet partner gets fast track for cancer vaccine

MAIA Biotechnology expands Phase 2 THIO-101 trial to Europe

Indaptus initiates Phase 1 trial of Decoy20 in advanced solid tumors

UT Southwestern performs 100th procedure with Profound’s TULSA-PRO

Context posts encouraging preliminary Phase 2 data in breast cancer

General

More